Overall survival (OS) for the combination versus sorafenib was the primary endpoint, while secondary objectives for the combination and Durvalumab alone were OS for Durvalumab over sorafenib, objective response rate, and progression-free survival (PFS). Tremelimumab and Durvalumab in combination demonstrated a good and significant OS benefit when compared to Sorafenib.

AstraZeneca, a British-Swedish pharmaceutical company, announced on Thursday that the Indian drug authority had approved its tremelimumab and anti-liver cancer medicine for use in India.
For the treatment of patients with unresectable hepatocellular carcinoma (uHCC), the injectable medications tremelimumab and durvalumab are recommended.